Virus Infection Recognition and Early Innate Responses to Non-enveloped Viral Vectors
Overview
Authors
Affiliations
Numerous human genetic and acquired diseases could be corrected or ameliorated if viruses are harnessed to safely and effectively deliver therapeutic genes to diseased cells and tissues in vivo. Innate immune and inflammatory response represents one of the key stumbling blocks during the development of viral-based therapies. In this review, current data on the early innate immune responses to viruses and to the most commonly used gene therapy vectors (using adenovirus and adeno-associated virus) will be discussed. Recent findings in the field may help develop new approaches to moderate these innate immune anti-viral responses and thus improve the safety of viral vectors for human gene therapy applications.
Temporal insights into molecular and cellular responses during rAAV production in HEK293T cells.
Patra A, Tan E, Kok Y, Ng S, Bi X Mol Ther Methods Clin Dev. 2024; 32(3):101278.
PMID: 39022743 PMC: 11253160. DOI: 10.1016/j.omtm.2024.101278.
Chatterjee A, Al Basir F, Biswas D, Abraha T Vaccines (Basel). 2022; 10(11).
PMID: 36366355 PMC: 9699126. DOI: 10.3390/vaccines10111846.
Noor F, Saleem M, Javed M, Chen J, Ashfaq U, Okla M PLoS One. 2022; 17(5):e0263901.
PMID: 35533150 PMC: 9084522. DOI: 10.1371/journal.pone.0263901.
Qian Z, Zhang Z, Wang Y PeerJ. 2019; 7:e7089.
PMID: 31223533 PMC: 6571000. DOI: 10.7717/peerj.7089.
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.
Duan D Mol Ther. 2018; 26(10):2337-2356.
PMID: 30093306 PMC: 6171037. DOI: 10.1016/j.ymthe.2018.07.011.